250 related articles for article (PubMed ID: 21334400)
1. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma.
Merani S; Majno P; Kneteman NM; Berney T; Morel P; Mentha G; Toso C
J Hepatol; 2011 Oct; 55(4):814-9. PubMed ID: 21334400
[TBL] [Abstract][Full Text] [Related]
2. An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma.
Kemmer N; Neff G; Kaiser T; Zacharias V; Thomas M; Tevar A; Satwah S; Shukla R; Buell J
Liver Transpl; 2006 Oct; 12(10):1519-22. PubMed ID: 17004260
[TBL] [Abstract][Full Text] [Related]
3. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation.
Toso C; Meeberg G; Hernandez-Alejandro R; Dufour JF; Marotta P; Majno P; Kneteman NM
Hepatology; 2015 Jul; 62(1):158-65. PubMed ID: 25777590
[TBL] [Abstract][Full Text] [Related]
4. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma.
Berry K; Ioannou GN
Liver Transpl; 2013 Jun; 19(6):634-45. PubMed ID: 23536495
[TBL] [Abstract][Full Text] [Related]
5. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.
Duvoux C; Roudot-Thoraval F; Decaens T; Pessione F; Badran H; Piardi T; Francoz C; Compagnon P; Vanlemmens C; Dumortier J; Dharancy S; Gugenheim J; Bernard PH; Adam R; Radenne S; Muscari F; Conti F; Hardwigsen J; Pageaux GP; Chazouillères O; Salame E; Hilleret MN; Lebray P; Abergel A; Debette-Gratien M; Kluger MD; Mallat A; Azoulay D; Cherqui D;
Gastroenterology; 2012 Oct; 143(4):986-94.e3; quiz e14-5. PubMed ID: 22750200
[TBL] [Abstract][Full Text] [Related]
6. Combination of biological and morphological parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation.
Lai Q; Avolio AW; Manzia TM; Sorge R; Agnes S; Tisone G; Berloco PB; Rossi M
Clin Transplant; 2012; 26(2):E125-31. PubMed ID: 22192083
[TBL] [Abstract][Full Text] [Related]
7. α-Fetoprotein is a potential survival predictor in hepatocellular carcinoma patients with hepatitis B selected for liver transplantation.
Zhang Q; Shang L; Zang Y; Chen X; Zhang L; Wang Y; Wang L; Liu Y; Mao S; Shen Z
Eur J Gastroenterol Hepatol; 2014 May; 26(5):544-52. PubMed ID: 24614696
[TBL] [Abstract][Full Text] [Related]
8. Serum alpha-fetoprotein response can predict prognosis in hepatocellular carcinoma patients undergoing radiofrequency ablation therapy.
Kao WY; Chiou YY; Hung HH; Su CW; Chou YH; Wu JC; Huo TI; Huang YH; Wu WC; Lin HC; Lee SD
Clin Radiol; 2012 May; 67(5):429-36. PubMed ID: 22153231
[TBL] [Abstract][Full Text] [Related]
9. Predictive Value of Alpha-fetoprotein in the Survival of Living Donor Liver Transplantation Recipients for Hepatocellular Carcinoma.
Jiang L; Liao A; Yan L; Li B; Zhu W; Wen T
Hepatogastroenterology; 2014 May; 61(131):747-51. PubMed ID: 26176068
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of absolute serum α-fetoprotein levels in liver transplant for hepatocellular cancer.
Mailey B; Artinyan A; Khalili J; Denitz J; Sanchez-Luege N; Sun CL; Bhatia S; Nissen N; Colquhoun SD; Kim J
Arch Surg; 2011 Jan; 146(1):26-33. PubMed ID: 21242442
[TBL] [Abstract][Full Text] [Related]
11. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
[TBL] [Abstract][Full Text] [Related]
12. Benefit of downsizing hepatocellular carcinoma in a liver transplant population.
Jang JW; You CR; Kim CW; Bae SH; Yoon SK; Yoo YK; Kim DG; Choi JY
Aliment Pharmacol Ther; 2010 Feb; 31(3):415-23. PubMed ID: 19821808
[TBL] [Abstract][Full Text] [Related]
13. Selective prognostic impact of serum alpha-fetoprotein level in patients with hepatocellular carcinoma: analysis of 543 patients in a single center.
Huo TI; Huang YH; Lui WY; Wu JC; Lee PC; Chang FY; Lee SD
Oncol Rep; 2004 Feb; 11(2):543-50. PubMed ID: 14719097
[TBL] [Abstract][Full Text] [Related]
14. Liver transplantation for hepatocellular carcinoma in New Zealand: a prospective intent-to-treat analysis.
Marui Y; McCall J; Gane E; Holden A; Duncan D; Yeong ML; Chow K; Munn S
N Z Med J; 2005 Jun; 118(1217):U1532. PubMed ID: 15980906
[TBL] [Abstract][Full Text] [Related]
15. Liver transplantation for hepatocellular carcinoma and cirrhosis in candidates with undetectable or very low alpha-fetoprotein levels: is an expansion of the listing criteria justified?
Sotiropoulos GC; Malagó M; Bockhorn M; Schmitz KJ; Radtke A; Molmenti EP; Schaffer R; Beckebaum S; Cicinnati VR; Fouzas I; Broelsch CE; Lang H
Hepatogastroenterology; 2008; 55(86-87):1671-7. PubMed ID: 19102367
[TBL] [Abstract][Full Text] [Related]
16. Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list.
Fisher RA; Maluf D; Cotterell AH; Stravitz T; Wolfe L; Luketic V; Sterling R; Shiffman M; Posner M
Clin Transplant; 2004 Oct; 18(5):502-12. PubMed ID: 15344951
[TBL] [Abstract][Full Text] [Related]
17. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
[TBL] [Abstract][Full Text] [Related]
18. Liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease era.
Levi DM; Tzakis AG; Martin P; Nishida S; Island E; Moon J; Selvaggi G; Tekin A; Madrazo BL; Narayanan G; Garcia MT; Feun LG; Tryphonopoulos P; Skartsis N; Livingstone AS
J Am Coll Surg; 2010 May; 210(5):727-34, 735-6. PubMed ID: 20421039
[TBL] [Abstract][Full Text] [Related]
19. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome.
Graziadei IW; Sandmueller H; Waldenberger P; Koenigsrainer A; Nachbaur K; Jaschke W; Margreiter R; Vogel W
Liver Transpl; 2003 Jun; 9(6):557-63. PubMed ID: 12783395
[TBL] [Abstract][Full Text] [Related]
20. Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients.
Cedrone A; Covino M; Caturelli E; Pompili M; Lorenzelli G; Villani MR; Valle D; Sperandeo M; Rapaccini GL; Gasbarrini G
Hepatogastroenterology; 2000; 47(36):1654-8. PubMed ID: 11149026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
